Consumption of systemic antibiotics in the Russian Federation in 2017–2021

Clinical Microbiology and Antimicrobial Chemotherapy. 2022; 24(3):220-225

​ Zakharenkov I.A., Rachina S.A., Kozlov R.S., Belkova Yu.A.
10.36488/cmac.2022.3.220-225
antibiotics АТС/DDD methodology consumption
Section
Antimicrobials
Type
Original Article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2022; 24(3):220-225

Objective.

To assess level and the structure of systemic antibiotic consumption in Russia over the period 2017 to 2021.

Materials and Methods.

Data were collected and analysed in compliance with the standard protocol of the World Health Organization Regional Office for Europe by the means of ATC/DDD methodology for J01 group – antibacterials for systemic use. Consumption was calculated for outpatients and inpatients separately as a number of DDDs per 1000 inhabitants per day (DID) for the main classes of antibiotics and the agents with the highest or the most diverse consumption levels for the given period of time, and was based on the data of wholesale purchases and public tenders.

Results.

Antibiotic consumption in Russia in 2017, 2018, 2019, 2020, and 2021 was 16.6 DID, 14.3 DID, 14.8 DID, 19 DID, and 15.7 DID respectively. Penicillins, macrolides and lincosamides, and quinolones had the highest levels of consumption in outpatients. Prominent increase in outpatient consumption of antibacterials in 2020 was related to three agents: azithromycin, levofloxacin and ceftriaxone. Cephalosporins (mainly III–V generations), quinolones and penicillins had the highest levels of consumption in inpatients. Hospital consumption of meropenem, tigecycline, and vancomycin increased and amikacin and ciprofloxacin decreased over the duration of the study.

Conclusions.

Levels of systemic antibiotic consumption in Russia for the period 2017 to 2019 were relatively low and consistent with the average means for European Union and European Economic Area countries. The steep increase in consumption in 2020 was probably due to the wide use of antibiotics for the management of COVID-19 patients. The results of the study can be of value for the development of targeted national antibiotic stewardship programs and awareness campaigns as well as for the analysis of trends of emergence and spread of antibiotic resistance.

Ivan A. Zakharenkov

City Clinical Hospital named after S.S. Yudin, Moscow, Russia

Svetlana A. Rachina

I.M. Sechenov First Moscow State Medical University, Moscow, Russia

Roman S. Kozlov

Smolensk State Medical University, Smolensk, Russia

Belkova Yu.A.

Smolensk State Medical University, Smolensk, Russia

  • 1. Dadgostar P. Antimicrobial resistance: implications and costs. Infect Drug Resist. 2019;12:3903-3910. DOI: 10.2147/IDR.S234610
  • 2. Cassini A., Högberg L.D., Plachouras D., Quattrocchi A., Hoxha A., Simonsen G.S., Colomb-Cotinat M., et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56-66. DOI: 10.1016/S1473-3099(18)30605-4
  • 3. Hofer U. The cost of antimicrobial resistance. Nat Rev Microbiol. 2019;17(1):3. DOI: 10.1038/s41579-018-0125-x
  • 4. Prestinaci F., Pezzotti P., Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015;109. DOI: 10.1179/2047773215y.0000000030
  • 5. Cao J., Song W., Gu B., Mei Y.N., Tang J.P., Meng L., et al. Correlation between carbapenem consumption and antimicrobial resistance rates of Acinetobacter baumannii in a university-affiliated hospital in China. J Clin Pharmacol. 2013;53(1):96-102. DOI: 10.1177/0091270011435988
  • 6. Medina E., Pieper D.H. Tackling threats and future problems of multidrug-resistant bacteria. Curr Top Microbiol Immunol. 2016;398:3-33. DOI: 10.1007/82_2016_492
  • 7. Karam G., Chastre J., Wilcox M. H., Vincent J. L. Antibiotic strategies in the era of multidrug resistance. Crit Care. 2016;20. DOI: 10.1186/s13054-016-1320-7
  • 8. Chaouch C., Hassairi A., Riba M., Boujaafar N. Relations entre la résistance bactérienne et la consommation des antibiotiques. Ann Biol Clin. 2014;72(5):555-560. DOI: 10.1684/abc.2014.0981
  • 9. McDonnell L., Armstrong D., Ashworth M., Dregan A., Malik U., White P. National disparities in the relationship between antimicrobial resistance and antimicrobial consumption in Europe: an observational study in 29 Countries. J Antimicrob Chemother. 2017;72(11):292300. DOI: 10.1093/jac/dkx248
  • 10. Arepyeva M.A., Kolbin A.S., Sidorenko S.V., Lawson R., Kurylev A.A., Balykina Y.E., et al. A mathematical model for predicting the development of bacterial resistance based on the relationship between the level of antimicrobial resistance and the volume of antibiotic consumption. J Glob Antimicrob Resist. 2017;8:148-156. DOI: 10.1016/j.jgar.2016.11.010
  • 11. Antimicrobial consumption database (ESAC-Net). Available at: www.ecdc.europa.eu/en/antimicrobial-consumption/surveillance-and-disease-data/database. Accessed August 01, 2022.
  • 12. Alawi M.M., Tashkandi W.A., Basheikh M.A., Warshan F.M., Ghobara H.A., Ramos R.B., et al. Effectiveness of antimicrobial stewardship program in long-term care: a five-year prospective single-center study. Interdiscip Perspect Infect Dis. 2022;2022:8140429. DOI: 10.1155/2022/8140429
  • 13. World Health Organization. Defined daily dose (DDD) 2021. Available at: www.who.int/tools/atc-ddd-toolkit/about-ddd. Accessed August 01, 2022.
  • 14. World Health Organization. ATC/DDD Index. 2021. Available at: www.whocc.no/atc_ddd_index/. Accessed August 01, 2022.
  • 15. Federal State Statistics Service. Available at: https://rosstat.gov.ru/folder/12781. Accessed August 01, 2022. Russian.
  • 16. WHO (2016). Global Action Plan on Antimicrobial Resistance. Available at: www.who.int/publications/i/item/9789241509763. Accessed August 01, 2022.
  • 17. WHO (2019). WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation. Available at: www.who.int/publications/i/item/who-report-onsurveillance-of-antibiotic-consumption. Accessed August 01, 2022.
  • 18. Antimicrobial consumption in the EU/EEA (ESAC-Net) – Annual Epidemiological Report for 2020. Stockholm: ECDC; 2021. Available at: www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-consumptioneurope-2020. Accessed August 01, 2022.
  • 19. Robertson J., Vlahović-Palčevski V., Iwamoto K., Högberg L.D., Godman B., Monnet D.L., et al. Variations in the consumption of antimicrobial medicines in the European region, 2014-2018: findings and implications from ESACNet and WHO Europe. Front Pharmacol. 2021;12:639207. DOI: 10.3389/fphar.2021.639207
  • 20. Rawson T.M., Moore L.S.P., Zhu N., Ranganathan N., Skolimowska K., Gilchrist M. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020;71:2459-2468. DOI: 10.1093/cid/ciaa530
  • 21. Lansbury L., Lim B., Baskaran V., Lim W.S. Co-infections in people with COVID-19: a systematic review and metaanalysis. J Infect. 2020;81:266-275. DOI: 10.1016/j.jinf.2020.05.046
  • 22. Langford B.J., So M., Raybardhan S., Leung V., Soucy J.P., Westwood D., et al. Antibiotic prescribing in patients with COVID19: rapid review and metaanalysis. Clin Microbiol Infect. 2021;1:18. DOI: 10.1016/j.cmi.2020.12.018
  • 23. Yang Y., Geng X., Liu X., Wen X., Wu R., Cui D., Mao Z. Antibiotic use in China's public healthcare institutions during the Covid-19 pandemic: an analysis of nationwide procurement data, 2018-2020. Front Pharmacol. 2022;13:813213. DOI: 10.3389/fphar.2022.813213
  • 24. Ng T.M., Tan S.H., Heng S.T., Tay H.L., Yap M.Y., Chua B.H., et al. Effects of Coronavirus Disease 2019 (COVID-19) pandemic on antimicrobial prevalence and prescribing in a tertiary hospital in Singapore. Antimicrob Resist Infect Control. 2021;10:28. DOI: 10.1186/s13756-021-00898-8
  • 25. Swedres-Svarm (2020). Sales of antibiotics and occurrence of resistance in Sweden. Available at: www.sva.se/media/8d9678c390929e9/swedres_svarm_2020.pdf. Accessed August 01, 2022.
  • 26. Gagliotti C., Buttazzi R., Ricchizzi E., Di Mario S., Tedeschi S., Moro M.L. Community use of antibiotics during the COVID-19 lockdown. Infect Dis (Lond). 2021;53(2):142144. DOI: 10.1080/23744235.2020.1834139
  • 27. Peñalva G., Benavente R. S., Pérez-Moreno M. A., PérezPacheco M. D., Pérez-Milena A., Murcia J., et al. Effect of the Coronavirus Disease 2019 pandemic on antibiotic use in primary care. Clin Microbiol Infect. 2021;27(7):10581060. DOI: 10.1016/j.cmi.2021.01.021
  • 28. Buehrl D.J., Wagener M.M., Hong Nguyen M., Clancy C.J. Trends in outpatient antibiotic prescriptions in the United States during the COVID-19 pandemic in 2020. JAMA Netw Open. 2021;4(9):e2126114. DOI: 10.1001/jamanetworkopen.2021.26114
  • 29. King L.M., Lovegrove M.C., Shehab N., Tsay S., Budnitz D.S., Geller A.I., et al. Trends in US outpatient antibiotic prescriptions during the Coronavirus Disease 2019 pandemic. Clin Infect Dis. 2021;73(3):e652-e660. DOI: 10.1093/cid/ciaa1896
  • 30. World Health Organization. Clinical management of COVID19 interim guidance, May 2020. Geneva: World Health Organization; 2020. Available at: www.who.int/publicationsdetail/clinicalmanagementofcovid19. Accessed August 01, 2022.
  • 31. Interim methodological recommendations. Prevention, diagnostics and treatment of new coronavirus infection (COVID19). Version 10. February 08, 2021. Available at: https://static0.minzdrav.gov.ru/system/attachments/attaches/000/054/588/original/%D0%92%D1%80%D0%B5%D0%BC%D0%B5%D0%BD%D0%BD%D1%8B%D0%B5_%D0%9C%D0%A0_COVID19_%28v.10%2908.02.2021_%281%29.pdf. Russian.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared